<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="108">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 29, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04334512</url>
  </required_header>
  <id_info>
    <org_study_id>PRG-044</org_study_id>
    <nct_id>NCT04334512</nct_id>
  </id_info>
  <brief_title>A Study of Quintuple Therapy to Treat COVID-19 Infection</brief_title>
  <acronym>HAZDpaC</acronym>
  <official_title>A Phase II Pilot Study of Quintuple Therapy to Treat COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProgenaBiome</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ProgenaBiome</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II interventional study will test the efficacy of quintuple therapy
      (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) in the treatment of
      patients with COVID-19 infection).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study patients will be treated with a combination therapy to determine if this
      combination can effectively treat COVID-19. The study will last 24 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label single group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful treatment as determined by Negative Test and resolution of symptoms</measure>
    <time_frame>24 weeks</time_frame>
    <description>Patients will experience complete resolution of symptoms and test negative for COVID-19</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of Quintuple Therapy</measure>
    <time_frame>24 weeks</time_frame>
    <description>Patients will tolerate Quintuple Therapy with minimal side effects. Meaning that side effects will not be severe enough to warrant discontinuation of therapy</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Quintuple Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with quintuple therapy for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>treatment with hydroxychloroquine</description>
    <arm_group_label>Quintuple Therapy</arm_group_label>
    <other_name>Plaquenil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Treatment with azithromycin</description>
    <arm_group_label>Quintuple Therapy</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vitamin C</intervention_name>
    <description>Treatment with vitamin c</description>
    <arm_group_label>Quintuple Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Treatment with vitamin D</description>
    <arm_group_label>Quintuple Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc</intervention_name>
    <description>Treatment with Zinc</description>
    <arm_group_label>Quintuple Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent, demonstrating that the subject understands the procedures
             required for the study and the purpose of the study

          2. Healthy male or female subjects 18 years of age to 55 years of age

          3. Subjects must agree to practice at least one highly effective method of birth control
             for the duration of the study

          4. Diagnosis of COVID-19 by RT-PCR

        Exclusion Criteria:

          1. Refusal to sign informed consent form

          2. Negative test for COVID-19 by RT-PCR at screening

          3. Diarrhea (prior to infection)

          4. Any comorbidities which, in the opinion of the investigator, constitute health risk
             for the subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine Hazan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ProgenaBiome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Hazan, MD</last_name>
    <phone>805-200-7436</phone>
    <email>sabinehazan@aim.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jordan Daniels, MS</last_name>
    <phone>217-494-6692</phone>
    <email>msjordandaniels@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ProgenaBiome</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

